On regional mix, he said the Americas now derive more than half of revenue from non-research segments (applied industrial, clinical, and biopharma). He contrasted that with EMEA, where research remains a larger share, and Asia-Pacific, where distributor reporting affects the way revenue is categorized.Keher emphasized that Oxford Nanopore saw growth across its product ranges and highlighted faster expansion in newer end markets. He said clinical revenue grew more than 60% for the year, biopharma grew 30% , ...